(Health-NewsWire.Net, September 16, 2018 ) This report covers the present scenario (with the base year being 2017) and the growth prospects of global Benign Prostatic Hyperplasia Drugs market for 2018-2023. Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth. The increasing demand for Benign Prostatic Hyperplasia (BPH) Drugs drives the market. Three factors contributing to the growth of the global benign prostatic hyperplasia drugs market are growing geriatric male population, strong r&d and growing demand for alpha-blockers. The evolution of alpha-blockers therapy for BPH has focused on improving convenience and tolerability. Reversing signs and symptoms or preventing progression of the disease are the indications of treating BPH. Alpha-blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Additionally, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual. Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH. This disorder affects one in 38 individuals in the age group of 40-59 years; however, in the age group of 60-69 years, it affects one in 14 individuals. The BPH drugs market in the Americas accounted for the majority market share during 2016 and the market in this region is likely to experience a high growth rate during the estimated period. Factors such as the growing demand for urology-related disorders and the increasing rate of geriatric men population, will stimulate the demand for BPH drugs and fuel the market’s growth. Over the next five years, this report projects that Benign Prostatic Hyperplasia (BPH) Drugs will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017. This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia (BPH) Drugs market by product type, application, key manufacturers and key regions. To calculate the market size, this report considers value and volume generated from the sales of the following segments: Segmentation by product type: Alpha-Blocker Phosphodiesterase Type-5 Inhibitors 5-Alpha-Reductase Inhibitors Segmentation by application: Men Women This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Spain Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Astellas Pharma Eli Lilly GlaxoSmithKline Sanofi ADC Therapeutics Bayer HealthCare Bristol-Myers Squibb Valeant Pharmaceuticals Endo Pharmaceuticals Foresee Pharmaceuticals In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development. Research objectives To study and analyze the global Benign Prostatic Hyperplasia (BPH) Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023. To understand the structure of Benign Prostatic Hyperplasia (BPH) Drugs market by identifying its various subsegments. Focuses on the key global Benign Prostatic Hyperplasia (BPH) Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Benign Prostatic Hyperplasia (BPH) Drugs with respect to individual growth trends, future prospects, and their contribution to the total market. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). To project the consumption of Benign Prostatic Hyperplasia (BPH) Drugs submarkets, with respect to key regions (along with their respective key countries). To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market. To strategically profile the key players and comprehensively analyze their growth strategies.
To get Free Sample or to Buy this report at discounted price visit: https://www.nxtgenreports.com/market-research-reports/2018-2023-global-benign-prostatic-hyperplasia-bph
If you have any special requirements, kindly Contact Us and we will offer you the report as you want.
About NxtGen Reports: NxtGen Reports delivers strategic market research reports, industry analysis, business research and forecasts on product, services and companies. We understand the need of our customers and keep our market research reports up to date. Our reports are very well organized enabling our customers to identify and get access easily. We also offer customized discounts based on your expectations.
Contact Information: Madhuri Vetal NxtGen Reports Email: sales@nxtgenreports.com Phone: +918551022388 More Report at: https://www.nxtgenreports.com/market-research-reports
NxtGen Reports
Madhuri Vetal
+918551022388
sales@nxtgenreports.com
Source: EmailWire.Com
|